Abstract Prior researches have suggested that homebased subcutaneous immunoglobulin (SCIG) is equally effective and can be less expensive than hospital-based intravenous immunoglobulin (IVIG) in treating chronic inflammatory demyelinating polyneuropathy (CIDP) patients. This economic evaluation aims at comparing costs of SCIG vs IVIG for CIDP patients in Italy. A 1-year model-based cost-minimization analysis basically populated via neurologists' opinion was undertaken from a societal perspective. Health care resources included immunoglobulin; drugs for premedication and complications (rash, headache, and hypertension) management; time of various health care professionals; pump for SCIG selfadministration; infusion disposables. Non-health care resources encompassed transport and parking; losses of working and leisure time for patients and caregivers. Unit or yearly costs for resources valuation were mainly obtained from published sources. Costs were expressed in Euro (€) 2013. An extensive one-way sensitivity analysis (OWSA) and a scenario SA tested the robustness of the base case findings. Overall costs per patient amount to €49,534.75 (SCIG) and €50,895.73 (IVIG); saving in favour of SCIG reaches €1360.98. For both SCIG and IVIG, the cost driver was immunoglobulin (94.06 vs 86.06 % of the overall costs, respectively). Sensitivity analyses confirmed the consistency of the baseline results. SCIG may be a cost-saving therapy for Italian CIDP patients.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder [1] . The course of CIDP may be chronic progressive, stepwise, or monophasic [2] .
Although CIDP is not age or gender-dependent, it is more frequent in older individuals and males [1] . Older age groups are more likely to have a chronic progressive course of CIDP, whereas a relapsing-remitting pattern is frequently observed in younger patients [3] .
The crude prevalence rate of CIDP in different countries has been reported to range between 0.8 and 7.7 per 100,000 population [4] [5] [6] , and falls in between these extremes (3.58 per 100,000 population) for two North-Western Italian Regions (Piedmont and Valle d'Aosta) [7] .
Prior researches have suggested that home-based subcutaneous immunoglobulin (SCIG) is equally effective and can be less expensive than hospital-based intravenous immunoglobulin (IVIG) in treating CIDP patients, due to savings on nursing and medical resources [8, 9] .
Expanding on the unique Italian economic evaluation on this topic [9] , this article reports on methods and result of a 1-year model-based cost-minimization analysis [10] aimed at comparing cost of SCIG vs IVIG for CIDP patients in Italy from the societal perspective [10] .
Methods
As the economic evaluation was not an empirical study, no ethics board approval was requested.
Cost-minimization analysis
Cost-minimization analysis compares solely in terms of cost two or more health care technologies proved to be equivalent in terms of clinical effectiveness [10, 11] .
Resource identification and quantification
Consistently with the societal standpoint, health care and non-health care resources were identified and quantified based on neurologists' opinion and research hypotheses ( Table 1) .
Health care resources included immunoglobulin, drugs for premedication and management of the complications (rash, headache, and hypertension) following infusion (IVIG only) [8, 9] , time of neurologist, nurse, general practitioner (GP), other specialist (IVIG only), Local Health Authority (LHA) pharmacist (SCIG only), pump for self-administration (SCIG only), and infusion disposables.
Assuming a patient weight of 80 kg, a monthly infusion scheme of 1 g of immunoglobulin per kg was considered. SCIG patients were assumed to self-administer 10 g of immunoglobulin twice per week (i.e. 96 administrations per year), and IVIG patients to receive 40 g of immunoglobulin twice per month in two subsequent days (i.e. 24 administrations per year) in hospital setting.
Non-health care resources encompassed transport and parking, as well as losses of working and leisure time for patients and caregivers.
Distance back and forth between patients' home and hospital (LHA) was estimated at 12 (6) km and travelled by car, whereas a walking distance of 2 km between patients' home and GP surgery was considered.
Parking duration was assumed to be 0.5 h longer than patients and caregivers' time loss, considering that they prefer to pay an extra amount for parking to avoid possible fines should any delay on scheduled parking time occur.
For both SCIG and IVIG, the proportion of employed patients and housewives was estimated at 0.46 and 0.14, respectively (the same proportions were assumed for caregivers), whereas the proportion of patients needing caregivers' support (i.e. informal car) [10, 11] was estimated at 0.04 (SCIG) and 0.4 (IVIG).
Patients and their caregivers were supposed to lose working time for attending two hospital-based training sessions for learning immunoglobulin self-administration only once before starting treatment (SCIG only); accessing GP surgery for recipes concerning neurologist visits, immunoglobulin infusions, and follow-up; accessing LHA for receiving immunoglobulin, disposables, and self-infusion pump (SCIG only); undergoing immunoglobulin administration in hospital setting (IVIG only), follow-up, and complications management (IVIG only).
Time spent by patients and caregivers included the distance travelled back and forth between home and hospital, LHA and GP surgery.
As no disruption in daily activities was assumed for SCIG patients, they were supposed to lose leisure time instead of working time for immunoglobulin self-administration.
Due to the limited time horizon, mortality was not taken into account.
Resource valuation
Unit or yearly costs for resource valuation were grouped into three categories that focus on who actually funds a given health care or non-health care resource [10] ( Table 2) .
The first category includes costs for drugs, inpatient and outpatient health care services provided by health care facilities and professionals within the health care sector (hospital, LHA, and GP).
The second category gathers patients' and their families' out-of-pocket expenses for health and non-health care resources, as well as productivity and leisure time losses incurred by patients and caregivers.
The third category includes costs borne by other sectors, such as those related to self-infusion pump and disposables (SCIG only), as in Italy these items are usually provided and funded by pharmaceuticals producing immunoglobulin, with no charge for hospital, LHA or patient.
Monetary values for resources different from patients, caregivers, and housewives' time were obtained from published sources [9, [12] [13] [14] [15] , estimated using tariffs for funding health care providers in Italy [16] assuming that they were a good proxy of the actual costs [17] , or retrieved via ad hoc researches (immunoglobulin; parking; selfinfusion pump and disposables for SCIG).
Immunoglobulin was valued using the average tender price per gram negotiated between pharmaceuticals and five Italian Regions (North East: 1; North West: 1; Centre: 1; South: 2) during the 1st quarter 2013, weighted for the relative population [18] to take into account potential differences in the exposition to immunoglobulin at local level.
Consistently with the useful life for a SCIG self-infusion pump, a 5-year straight-line depreciation approach [10] was adopted for calculating the yearly cost of this device. Therefore, the yearly cost of a SCIG self-infusion pump equals one-fifth of its purchase cost. No maintenance or replacement cost for SCIG self-infusion pump was considered. Health care sector costs do not include a share of overheads to be attributed to LHA and hospital.
No co-payment for drugs or health care services was included among out-of-pocket expenses, as in Italy CIDP patients can apply for a disease-based exemption [19] .
Time off paid work (leisure time) was valued using the average gross (net) annual wage rate for different professional categories, whereas housewives' time was costed using the average gross hourly cost of a patient companion [20] [21] [22] [23] [24] [25] [26] [27] .
All costs were expressed in Euro (€) 2013 and updated to this year according to proper inflation rates whenever necessary [28] .
Yearly costs for patient on SCIG or IVIG and their difference were calculated.
Since the economic evaluation stretches over 1-year time horizon, no discounting procedure was performed [10, 11] .
Statistical analysis
For most of the parameters included in the model, the 95 % confidence interval (95 % CI) was calculated via the percentile method [29, 30] .
An appropriate statistical distribution was given to each parameter and a reasonable coefficient of variation was applied to their base case estimate to obtain the standard error (SE) [30] [31] [32] . The SE for proportions was calculated assuming a sample of 100 patients (Table 3) .
No hypothesis testing was undertaken.
Sensitivity analysis
Sensitivity analysis (SA) allows for uncertainty in economic evaluation of health care programmes [10, 11] . A one-way SA (OWSA)-in which model parameters were changed one at time by replacing the base case estimate with the lower and the upper limits of 95 % CI while keeping the other parameters at their baseline levels [10, 11] -was carried out on: hourly cost of health care professionals, patients, caregivers, and parking; cost of immunoglobulin, disposables, self-infusion pump for SCIG, and electromyography; patient weight; number of administrations per year and their duration; number of LHA admittances per year (SCIG only); distance between patient's home and hospital; proportion of employed patients, housewives and caregivers; and frequency of complications for (IVIG only).
The results of OWSA were plotted on a Tornado chart. The y and x axes of Tornado chart crossed at the base case result.
A scenario SA [10, 11] was performed to investigate the impact on base case results due to shifting the cost for self- 
Results

Base case analysis
Overall costs per patient amount to €49,534.75 and €50,895.73 for SCIG and IVIG, respectively; saving in favour of SCIG reaches €1,360.98 (Table 4) . For both SCIG and IVIG, health care sector costs (94.83 vs 92.53 % % of the overall costs, respectively) are driven by immunoglobulin (94.06 vs 86.06 % of the overall costs, respectively).
Conversely, the impact of out-of-pocket expenses, working and leisure time losses is limited, especially for SCIG (2.79 vs 7.47 % of the overall costs, respectively). Saving in favour of SCIG is mainly explained by a lower need for informal care (€9.32 vs €951.26) and reduced time losses due to immunoglobulin administration (€996.94 vs €1,863.39).
Eventually, other sector costs show a quite negligible effect on overall costs for SCIG (2.38 %).
Sensitivity analysis
For the sake of brevity, only the results of OWSA concerning the ten parameters causing the widest variation in Interestingly, even if pharmaceuticals producing SCIG ceased to provide self-infusion pump and disposables free of charge and costs related to those essential components for SCIG therapy (€1,177.36) were shifted to hospital or patient and their family budget, the overall saving in favour if SCIG would remain unvaried (€1,360.98) ( Table 5) .
Discussion
By adopting a 1-year time horizon and the Italian societal perspective, this model-based cost-minimization analysis confirms that, given the same effectiveness [8, 9] , SCIG seems cost saving when compared with IVIG. If only half of the prevalent 2,126 CIDP patients estimated for Italy [7, 18] were prescribed SCIG instead of IVIG, saving for society and health care sector would reach €1.45 and €0.13 million, respectively.
It is worth noting that, even without adjusting for inflation, the base case saving in favour of SCIG could have been fourfold if the standard cost per gram of IVIG reported by the Italian National Blood Centre (€49.95, 2011 values) [33] instead of the weighted average tender price had been used. This is the first Italian economic evaluation that compares SCIG vs IVIG in CIDP patients following a viewpoint wider than the third-party payer perspective. Therefore, saving in favour of SCIG is higher than the one previously reported in the unique cost-minimization analysis on the same topic performed in Italy [9] because, consistently with the adopted standpoint, that research did not include cost categories other than health care sector costs funded by Piedmont Health Service.
The results of our research support the evidence that preferring SCIG vs IVIG generates saving also for hospital. Interestingly, saving at hospital level is due to a sort of ''informal partnership'' between health care sector and pharmaceuticals producing SCIG. However, scenario SA proved that, under the societal viewpoint, the overall saving in favour of SCIG would not change event if costs for self-infusion pump and disposables were borne by hospital or patient and their family instead of pharmaceuticals producing SCIG. As SCIG self-administration affects patients' leisure time only, the potential productivity loss for society due to CIDP is higher for IVIG. How the absence of disruption in working and daily activities, as well as the time saved from moving back and forth between home and hospital for immunoglobulin administration, improves SCIG patients' health-related quality of life (HRQoL) is still debated [9, 34] and shall benefit from further investigations on samples of patients of adequate size.
This economic evaluation has two main limitations. Firstly, due to a remarkable lack of patient level comparative research on the health economics of SCIG vs IVIG in CIDP, our cost-minimization analysis is based on a model that relied heavily on experts' opinions about resource consumption and loss induced by CIDP management. However, modelling was previously utilized for the economic evaluation of CIDP treatment in Canada and Italy [1, 9] . Moreover, supporting Italian decision-makers in choosing between SCIG and IVIG on the grounds of the results of a model-based cost-minimization analysis is, in all likelihood, better than providing them with no guidance at all [35, 36] .
The second limitation rests on the fact that the health care professionals whose qualified opinions were substantive for model population work in the same neurological department, which is at the forefront in CIDP treatment in Italy [37] . Therefore, model assumptions may have been different had a random sample of Italian neurological wards dealing with CIDP treatment been drawn for this research.
Being aware of the above-mentioned limitations, we tested the robustness of the base case findings via an extensive OWSA and a scenario SA.
In conclusion, the results of our research would endorse SCIG for CIDP treatment also from an economic point of view. However, as our results are far from being conclusive, there is an apparent necessity to carry out long-term empirical studies that can contribute to address the health economic and HRQoL issues related to the comparison of SCIG vs IVIG in treating CIDP patients in Italy.
